We have recently shown that lysine mutations in p53's putative C-terminal acetylation sites result in increased stability and cytoplasmic distribution of the p53 protein in a human lung cancer cell line. In the present study, we showed that when lysine residues 372, 373, 381, and 382 of p53 were substituted with alanine, the resulting A4 protein was resistant to MDM2-mediated proteosomal degradation but was highly sensitive to human papillomavirus E6-mediated proteolysis. When A4 and wildtype p53 were transfected into MDM2-overexpressing MCF-7 cells, A4 signi®cantly reduced colony formation in vitro, when compared with wild-type p53. Our results suggest that A4 exerts a growth-inhibitory eect more eciently than wild-type p53 does in cell lines that overexpress MDM2 and may therefore be a better therapeutic tool than wild-type p53 for certain cancers in which MDM2 is ampli®ed or overexpressed.
The p53 tumor suppressor, which is mutated in a variety of cancers, suppresses tumor cell growth mainly by inducing cell-cycle arrest and apoptosis (Oren and Rotter, 1999; May and May, 1999; Levine, 1997) . Regulation of p53 stability plays a pivotal role in modulating these functions (Ashcroft and Vousden, 1999; Oren, 1999) . The half-life of wild-type p53 in normal tissue is limited to minutes. However, several cellular stress, such as ionizing radiation, led to stabilization of p53 protein and activation of p53-mediated checkpoint functions. Several proteins are known to aect p53 stability through protein-protein interactions, including p19 ARF (Zhang et al., 1998) , p300 (Grossman et al., 1998) , E6 (Huibregtse et al., 1991) , WT-1 (Maheswaran et al., 1995) , E1B 55K/ E4orf6 (Querido et al., 1997) , SV40 large T antigen (Tiemann et al., 1995; Reihsaus et al., 1990) , JNK (Fuchs et al., 1998a) , HIF-1 (An and Kanedal, 1998) , TAF ii 31 (Buschmann et al., 2001 ) and MDM2 (Haupt et al., 1997; Kubbutat et al., 1997) . MDM2, a cellular oncoprotein, is a key negative regulator of p53 that blocks p53's transcriptional activity and abilities to induce growth arrest and apoptosis (Momand and Zambetti, 1997 for review) . Importantly, MDM2 also promotes the rapid degradation of p53 through the ubiquitin-mediated proteosomal pathway (Haupt et al., 1997; Honda and Yasuda., 1999; Kubbutat et al., 1997) . Since MDM2 is a direct target gene of p53, it shuts down its own expression through a negative autoregulatory feedback loop.
The MDM2 protooncogene is over-expressed and ampli®ed in certain human tumors (Freedman et al., 1999) . The tumorigenic activity associated with a high level of MDM2 expression may be due to its ability to target p53 for degradation, leading to inhibition of p53-induced cell-growth arrest and apoptosis although MDM2 has also been found to induce spontaneous tumorigenesis independent of p53 (Jones et al., 1998) . Over-expression of p53 induces the expression of MDM2, which binds the transactivation region of p53 and inhibits its ability to stimulate transcription (Momand et al., 1992; Prives, 1998) .
The E6 protein encoded by the oncogenic human papillomavirus also targets p53 for ubiquitin-dependent proteolysis (Schener et al., 1990) . E6-mediated p53 degradation requires the 100 kDa E6-associated protein (E6-AP) (Talis et al., 1998) . The E6/E6-AP complex binds to and targets p53 for ubiquitinmediated proteolysis. E6-AP acts as an E3 ubiquitin ligase, which accepts ubiquitin from an E2 ubiquitinconjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (Huibregtse et al., 1995) .
In this study, we sought to determine whether mutations in the C-terminal domain of p53 could enhance p53 stability through inhibition of E6-mediated or MDM2-mediated proteosomal degradation. Such a modi®ed p53 gene could serve as an eective therapeutic agent in several cancers that overexpress MDM2.
Site-directed mutagenesis was used to change the lysine residues at four putative acetlyation sites (371, 372, 381, and 382) in the C-terminal domain of p53 into alanine residues, to neutralize the positively charged lysine residues. The Wild-type p53 and modi®ed p53 (A4) constructs were sub-cloned into pRc/CMV, a constitutively expressed vector (Figure 1) , and transfected into the H1299 human lung cancer cell line. Expression of wild-type p53-induced cell cycle arrest and apoptosis in this cell line. As a result, no stable cell clones were obtained. Therefore, plasmids carrying either the wild-type p53 gene or the A4 gene were transiently transfected into a p53-null H1299 cell line, and p53 expression was analysed using Western blotting. Both A4 and wild-type p53-transfected cells expressed a signi®cant amount of protein 18 h after transfection (Figure 2a) . Although A4 was detected by monoclonal antibody PAb1801, which recognizes amino acids 46-55 of the p53 protein, it was not detected by monoclonal antibody PAb421, which recognizes p53's C-terminal domain. A4 was transcriptionally active and induced expression of endogenous p21 protein in the H1299 cell line. We have not seen any signi®cant increase in Bax protein in A4 expressing cells. Other laboratories have not been successful in seeing substantial upregulation of Bax in transfected H1299 cells. It also showed a strong DNA-binding activity (Figure 2b) .
Another major biochemical function of p53 is sequence-speci®c transcriptional transactivation, so we next compared the transactivational activities of wildtype p53 and A4. Plasmids expressing either wild-type p53 or A4 under a cytomegalovirus promoter, were cotransfected with the Cyclin G promoter luciferase reporter plasmid into p53-null H1299 cells. Cyclin G promoter is positively upregulated by wild-type p53. As shown in Figure 2c , wild-type p53 and A4 showed comparable transcriptional activation of the reporter, although wild-type p53 activated transcription to a marginally higher level than did A4. The dierences in the abilities of wild-type and modi®ed p53 to activate transcription may, at least in part, have been due to their dierential abilities to bind other basal transcriptional components rather than to their abilities to bind consensus DNA itself. Thus, wild-type p53 and A4 did not seem biochemically equivalent.
The increased level of A4 protein could have been due to post-transcriptional modi®cation that conferred resistance to proteolysis by either MDM2 or E6. To explore which mechanisms of A4 degradation were being used, we transiently cotransfected H1299 cells with either wild-type p53 or A4 and either MDM2 or E6 expression plasmids. Total cell extracts were analysed for p53 and A4 expression using anti-p53 monoclonal antibodies. Interestingly, wild-type p53 was degraded in cells expressing either MDM2 or E6, but A4 was degraded only in cells expressing E6; A4 accumulated in MDM2-expressing cells (Figure 3a,b) . These results indicated that E6 did not require MDM2 for degradation of either wild-type p53 or A4. When a p53175His mutant cDNA was cotransfected into H1299 cells with either MDM2 or E6, MDM2 more eectively mediated degradation of the mutant p53 than E6 did (Figure 3c ). Both wild-type p53 and A4 were sensitive to E6-mediated proteolysis. These results suggested that although the ubiquitination pathway degraded both proteins, the mechanisms of degradation need further elucidation.
It has been shown that the adenoviral protein E1A stabilizes wild-type p53. Therefore, we sought to determine whether A4 interfered in E1A-mediated stabilization of p53. E1A and MDM2 expression plasmids were cotransfected with wild-type p53 or A4 into H1299 cells, and the proteins were analysed by Western blotting, as shown in Figure 3d . We quantitated p53 band intensities and normalized with corresponding actin protein using NIH image analysis software. Quantitative comparison of signals between p53 and E1A/p53 (lanes 1 and 3) indicated that E1A stabilized wild-type p53 in E1A-expressing cells where p53 ratio was increased to 1.3-fold. MDM2 caused almost a complete degradation of wild-type p53. On the other hand, when we compared the normalized values of A4 and A4/E1A (lanes 4 and 6), no change in the level of A4 in E1A-transfected cells was noticed (1.0-fold). Thus, these results suggest that the modi®cation of the C-terminal domain of p53 plays a role in interaction with proteins in addition to MDM2.
Having established that wild-type p53 and A4 were comparable in their transcriptional activities and were functionally similar, we next compared the growthinhibitory eects of the two proteins by comparing their abilities to suppress the proliferation of cell lines overexpressing MDM2. We examined MDM2 expression in four cell lines using Western blot analysis with anti-MDM2 antibodies, as shown in Figure 4a . We found that MCF-7 cells constitutively expressed high levels of MDM2. Assuming that A4 would be more stable in cell lines that over-expressed MDM2, we determined whether A4 could produce a superior growth inhibition in these cell lines, as compared to that produced by wild-type p53. Therefore, we used MCF-7 and H1299 p53-null cell lines that expressed no detectable MDM2 for transformation-suppression studies. Wild-type p53 or A4 cDNAs were cotransfected with a pRc/CMV vector (which included G418 resistant gene marker) into H1299 and MCF-7 breast cancer cell lines, and stable G418-resistant colonies were selected. After 2 weeks of G418 selection, the cells were ®xed and stained with crystal violet. The colonies were then counted (Figure 4b ). It was clear that in H1299 cells, wild-type p53 and A4 were similarly ecient in suppressing cellular transformation. In addition, colonies that proliferated for more than the 2-week period did not expand further, indicating that both forms of p53 caused a complete cessation of cell proliferation. In MCF-7 cells, A4 was signi®cantly more active in suppressing colony formation than wildtype p53 was (P50.02). This result further suggested that high levels of endogenous MDM2 prevented wildtype p53 from exerting its eects in MCF-7 cells. Therefore, A4 appeared to be superior to wild-type p53 as in an inhibitor of cellular proliferation in cancer cells that over-express MDM2.
Although the MDM2 and human papiloma virus protein E6 both are involved in p53 degradation, a precise map of the ubiquitination sites on p53 is not yet available. It is possible that the balance between E6 and MDM2 determines p53 levels. This emerging model suggests that the contribution of dierent factors to p53 stability depends on cell context, cellcycle progression, and cell-stressing signals.
The interactions of MDM2 and E6 with Cterminally modi®ed p53 are not well known. It has been published that multiple C-terminal lysine residues target p53 its degradation (Rodriguez et al., 2000) . We have previously shown that A4 is less ubiquitinated than is wild-type p53 and is therefore not degraded eciently by MDM2 mediated degradation (Nakamura et al., 2000) . The possibility exists that the four lysine residues that have been changed to alanine residues in A4 are potential sites for ubiquitination and are required for proteosome-mediated degradation. However, this is not likely since in the present study, we found that A4 could be eciently degraded by E6, which also utilizes the ubiquitination pathway for Figure 2 Expression and transcriptional activation of wild-type p53 and A4 in H1299 cells. (a) Western blot analysis of wild-type p53 and A4 in a p53-null H1299 cell line. H1299 cells were transfected with 1 mg of vector alone, wild-type p53 cDNA, or A4 cDNA and seeded at a density of 3 ± 4610 5 cells per well in 6-well plates. They were transfected the following day with 1, 2-dioleoyl-3-(trimethylammonium) propane (DOTAP); Boehringer Mannheim) according to the manufacturer's instructions. The p53 and A4 proteins were detected using anti-p53 monoclonal antibody PAb1801 (Oncogene Research Products). Endogenous p21WAF1 or Bax proteins were detected using anti-p21 WAF1 or anti-Bax monoclonal antibodies. Actin was used as a loading control. (b) Nuclear extractions and electromobility shift assays were performed as previously described (Nakamura et al., 2000) using the p53 consensus DNA-binding sequence (p53CON) GGACATGCC-CGGGCA TGTCC and either wild-type p53 or A4. The following antibodies were used for supershift assay: Ab-1, PAb 421, Ab-2, Pab-1801, and Ab-6, DO1 (Oncogene Sciences). NC, non-speci®c competitor, IC, poly (dI-dC), P, PUC9 plasmid DNA, N, non-speci®c NF-kB oligonucleotides. Reaction mixtures were then loaded onto a native 4% polyacrylamide gel (acrylamide: Bis-acrylamide, 29 : 1) containing 0.56 Tris-borate-EDTA (TBE) and electrophoresed in 0.56 TBE at 100 ± 150 V for 2.5 h at 48C. After drying, gels were exposed to a phosphor screen and analysed using the STORM 860 imager (Molecular Dynamics). The upper arrow indicates a supershifted band and the lower double arrow shows unbound p53 and A4. (c) Transcriptional activation of the cyclin G promoter by wild-type p53 or A4. H1299 p53-null cells were cotransfected with 1 mg of vector alone, wild-type p53 cDNA, or A4 cDNA and 1 mg of a luciferase reporter construct containing the cyclin G promoter. Luciferase activity was assayed 48 h after transfection. Total protein concentrations were determined using the BCA protein assay kit (Pierce). Each sample (5 ± 20 ml) was mixed with 100 ml of luciferase assay substrate that was reconstituted with luciferase assay buer (Promega Corp.). Light emission was determined using a luminometer (Monolight 2010; Analytical Luminescence Laboratory). Luciferase activity was normalized according to protein concentration. Results were given as the average of at least three independent experiments protein degradation. Although the mechanism by which A4 is protected from MDM2-mediated degradation is not clear, the possibility exists that binding of p53 to MDM2 is not the only determinant of ubiquitination and degradation. When A4 was cotransfected with E1A expression plasmids, A4 protein levels were marginally increased, suggesting that A4 is less reactive to E1A-induced modi®cation that stabi- Figure 3 A4 is resistant to MDM2-mediated degradation but not to E6-mediated proteolysis. H1299 cells were transfected with 5 mg of either one of the indicated plasmids or a combination of plasmids. Twenty-four hours after transfection, cell extracts were prepared, and expression of p53 and p21 were analysed by Western blot analysis using anti-p53 polyclonal antibody PAb1801 and anti-p21 monoclonal antibodies. (a) In cells cotransfected with MDM2 and either wild-type p53 or A4, p53 levels were signi®cantly reduced but A4 expression was stable. Expression of p21 was reduced due to excess MDM2 that interfered with the DNA-binding activity of p53. (b) Western blot showing that A4 was degraded as eectively by E6 as was wildtype p53. (c) Cotransfection of mutant p53 (His175) with either MDM2 or E6 plasmids into H1299 cells showed that although both MDM2 and E6-mediated degradation of the mutant p53, they more eciently mediated degradation of wild-type p53 or A4. (d) Cotransfection of wild-type p53 or A4 with E1A showed that A4 expression was marginally elevated following E1A transfection Figure 4 In cell lines that over-expressed MDM2, A4 caused stronger growth suppression in colony-formation assays than wild-type p53 did. (a) Protein from four dierent cell lines overexpressing endogenous MDM2 protein was examined by Western blot analysis using anti-MDM2 antibodies. Blots were then reprobed with anti-p53 and anti-actin monoclonal antibodies. (b) MCF-7 and p53-null H1299 cells were seeded at 5610 5 cells per 10-cm dish and transfected with indicated plasmid constructs using DOTAP. Cells were maintained in RPMI medium containing 5% fetal bovine serum and G418 (300 mg/ ml). The medium was changed every 3 days, and after 14 days, the plates were stained with Giemsa (Sigma) and colonies were counted. The experiments were performed in triplicate and demonstrated similar results lizes wild-type p53. How modi®cations on the Cterminus of p53 interfere with proteins that bind p53's N-terminus needs to be further evaluated.
In the present study, we also compared the abilities of the wild-type p53 and A4 proteins to inhibit cellular proliferation in cancer cells expressing high or low levels of MDM2. In colony-formation assays in H1299 cells, wild-type p53 and A4 inhibited cell proliferation to a similar degree. However, in MCF-7 cells, A4 suppressed transformation to a higher degree than wild-type p53 did. This was interesting, since previous reports had suggested that suppression of transformation by p53 closely correlates with its ability to induce apoptosis (Thomas et al., 1996) . Taken together, these data suggest that A4 induce apoptosis more eciently than does wild-type p53. Our observations also suggest that wild-type p53 and A4 proteins are not biochemically or biologically equivalent and that A4 possesses a gain-of-function mutation.
The major roles of p53 are to induce G 1 cell-cycle arrest and apoptosis, particularly after DNA damage. These two activities are regulated by the product of the mdm2 oncogene product (Chen et al., 1996; Haupt et al., 1996; Wadgaonkar and Collins, 1999) . MDM2 physically binds the transcriptional activation domain of p53 and presumably inhibits its ability to interact with transcription factors that regulate p53 target genes that are involved in anti-proliferative function (Momand et al., 1992; Finlay, 1993; Oliner et al., 1993) . Another mechanism by which MDM2 inactivates p53 is by promoting p53 degradation in a proteosomedependent manner (Haupt et al., 1997b; Kubbutat et al., 1997 Fuchs et al., 1998b) . MDM2 possesses an ubiquitin ligase function and is involved in controlling p53 metabolic stability, which is a critical determinant of p53 function. Therefore, MDM2 serves in a feedback loop to down-regulate p53 function during cell-cycle progression in normal cells.
Since over-expression of MDM2 has been implicated in oncogenic transformation, it could lead to rapid degradation of p53 in cancer cells and thereby, to abrogation of p53 regulation. Accordingly, gene-replacement strategies that transfer wild-type p53 into cancer cells that over-express MDM2 are not likely to be therapeutically eective. Gene therapy trials with p53 are ongoing in lung cancer and head and neck cancers. Cells that harbor wild-type p53, and therefore retain relatively high levels of MDM2 when compared with cells containing nonfunctional p53 or naturally low levels of MDM2, are resistant to p53-mediated apoptosis. On the other hand, ampli®cation of the MDM2 gene and high levels of MDM2 expression have been noted in certain types of cancer, such as sarcomas. It has also been previously shown that cancer cells that over-express MDM2 are often resistant to gene therapy with wild-type p53 that is administered by direct DNA transfection or adenovirus-mediated gene transfer (Chen et al., 1996; Meng et al., 1998) . Therefore, molecular intervention that protects p53 from MDM2-mediated degradation may be a useful therapeutic tool. A4 retains the wild-type p53 transcriptional activation and G 1 growth-arrest functions. In fact, it has been shown that A4 mutants elicit a much stronger G 1 growth arrest than does wildtype p53 (Nakamura et al., 2002) . In MCF-7 cells, A4 is resistant to MDM2-mediated degradation and retains growth suppression in the presence of high levels of MDM2. Similarly, multiple lysine substitutions in p53 may have a clinical implication, particularly for human cancers that over-express MDM2.
